Pharmaceuticals

Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005

SUZHOU, China, April 20, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of i...

2021-04-20 20:54 1096

Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day

VANCOUVER, BC and TORONTO, April 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancers applications, announced today its sponsorship of this year's World Ovarian Cancer Day, a ...

2021-04-20 20:00 3826

AACR 2021-ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration

SHENZHEN, China, April 19, 2021 /PRNewswire/ -- On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting. MVR-T3011 is a replication competent and genetically modified oncolyti...

2021-04-20 08:30 1670

Abbott's Fast, Reliable and Convenient COVID-19 Tests Help the Philippines Fight Infection Surge

- Philippines scales its testing capability with two Abbott tests – a quick, patient-friendly rapid antigen test and lab-based quantitative antibody test - The Abbott Panbio™ COVID-19 Antigen Rapid Test Device comes with an easy-to-use nasal swab to detect active coronavirus infections in as earl...

2021-04-20 06:00 4799

Himalaya Therapeutics Announces Appointment of Nicholas Desjardins as Chief Financial Officer

SAN DIEGO, April 20, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based ...

2021-04-20 01:42 2047

China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port

HAIKOU, China, April 19, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Rel...

2021-04-19 20:30 3066

CNPharm has succeeded in maintaining IC100 for 24 hours with one injection

- Trail-blazing diversification of the repurposing of Niclosamide - Full-scale clinical preparation of injections for severely ill patients SEOUL, South Korea, April 19, 2021 /PRNewswire/ -- Hyundai Bioscience (Symbol 048410), a KOSDAQ listed company, announced on the 19th that its major sharehol...

2021-04-19 20:15 1615

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a leading ...

2021-04-19 17:54 3491

Transcenta Announced Successful First Patient Dosed in Phase I Clinical Study of TST001 Combined with CAPOX for the Treatment of Patients with First-line Locally Advanced Unresectable or Metastatic Gastric Cancer

SUZHOU, China, April 18, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the first patient has been success...

2021-04-19 08:00 1731

Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC

SEOUL, South Korea and JINAN, China, April 16, 2021 /PRNewswire/ -- Peptron, Inc. ("Peptron", KOSDAQ: 087010), aSouth Korea-based biotech company, and Qilu Pharmaceutical ("Qilu"), a leading vertically integrated pharmaceutical company focused on discovering, developing, manufacturing and commerc...

2021-04-16 20:00 4009

Kintor Pharmaceuticals Announced Successful Dosing of the First Batch of Patients for Acne Vulgaris Phase I/II Clinical Trial of Pyrilutamide

SUZHOU, China, April 16, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today the clinical trial of Pyrilutamide as a treatment for the acne vulgaris has completed the first b...

2021-04-16 18:29 5489

GT Apeiron Therapeutics Strengthens Advisory Board

SHANGHAI, April 16, 2021 /PRNewswire/ -- Keith Lenden and Dr. Honggang Bi has been appointed as new members of the Advisory Board at GT Apeiron Therapeutics, an AI empowered drug discovery start-up developing oncology therapeutics. Mr. Lenden and Dr. Bi add further expertise in drug discovery inn...

2021-04-16 09:00 2011

Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China

SUZHOU, China, April 15, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has received approval from t...

2021-04-15 18:20 5249

Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive

SINGAPORE, April 15, 2021 /PRNewswire/ -- Juniper Biologics, a science-led healthcare company focused on researching, developing & commercialising novel therapies, has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive. Juniper Biologics wi...

2021-04-15 16:30 2237

New clinical study shows JOYSBIO COVID-19 neutralizing antibody rapid test nearly 98% accurate in verifying antibodies after vaccination

TIANJIN, China, April 15, 2021 /PRNewswire/ -- In a major breakthrough for testing COVID-19 immunity, JOYSBIO, a Chinese medical device manufacturer, just announced the completion of a clinical study inItaly, showing their COVID-19 neutralizing antibody rapid test kit is 98.05% effective in detec...

2021-04-15 14:20 2657

Seegene's Italy subsidiary secures public procurement for 7.15 million COVID-19 diagnostic tests, the largest tender in history

* Seegene's Italian subsidiary to supply some 7.15 million COVID-19 tests to 17 regions there * S. Korean biotechnology firm to expand its influence in Italy's PCR diagnostic industry SEOUL, South Korea, April 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading molecular diagnostics ...

2021-04-15 14:19 1746

Everest Medicines Appoints Jennifer Yang as Chief Scientific Officer

SHANGHAI, April 15, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater ...

2021-04-15 08:36 5326

Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial Cancer

SHANGHAI, April 14, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater ...

2021-04-14 21:33 6237

Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41

SHANGHAI, April 14, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), fully dedicated to the R&D and commercialization of new drugs in the field of non-alcoholic steatohepatitis (NASH), today announces the dosing of the first cohort in the U.S. Phase I cli...

2021-04-14 20:00 3370

BioVaxys Announces Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology

VANCOUVER, BC, April 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancers applications, is pleased to announce the results of a clinical study conducted by ProCare Health Iberia...

2021-04-14 20:00 6858
1 ... 247248249250251252253 ... 314

Week's Top Stories